Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current advances in drug development in spinal muscular atrophy.

Current opinion in pediatrics - 1 Dec 2013

Singh Priyamvada, Liew Wendy K M, Darras Basil T

Abstract excerpt

PURPOSE OF REVIEW: Spinal muscular atrophy (SMA) is a pediatric neuromuscular condition characterized by progressive proximal muscle weakness. It is one of the most common genetic causes of infant mortality across different races and is caused by mutation of the survival of motor neuron 1 (SMN1) gene on chromosome 5q13. RECENT FINDINGS: To date, there have been many therapeutics developments for SMA targeting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Muscular Atrophy, Spinal
Share to Drug Design
Share to Hydroxyurea

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neuroprotective Agents

Share to Stem Cell Transplantation

Share to Survival of Motor Neuron 1 Protein

Share to Survival of Motor Neuron 2 Protein

Share to Valproic Acid

Source

Identifiers

PMID: 24240287
DOI: 10.1097/MOP.0b013e32836565ac

Genes

SMN1
SMN2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current advances in drug development in spinal muscular atrophy.PMID 24240287Read ↗

Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy TherapySemantic proximity Read ↗

Advances in Therapeutic Development for Spinal Muscular AtrophySemantic proximity Read ↗

Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.Semantic proximity Read ↗

Spinal muscular atrophy: a timely review.Semantic proximity Read ↗

Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent LandscapeSemantic proximity Read ↗

New Directions for SMA TherapySemantic proximity Read ↗

Molecular, genetic and stem cell-mediated therapeutic strategies for spinal muscular atrophy (SMA).Semantic proximity Read ↗

Current and emerging targeted therapies for spinal muscular atrophy.Semantic proximity Read ↗

New treatments in spinal muscular atrophy.Semantic proximity Read ↗

New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?Semantic proximity Read ↗

Spinal muscular atrophy: from gene discovery to clinical trials.Semantic proximity Read ↗

An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular AtrophySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.